Kaneko, H.; Kuroshima, S.; Kozutsumi, R.; Al-Omari, F.A.; Hayano, H.; Nakajima, K.; Sawase, T.
Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like Lesions. J. Clin. Med. 2023, 12, 1914.
https://doi.org/10.3390/jcm12051914
AMA Style
Kaneko H, Kuroshima S, Kozutsumi R, Al-Omari FA, Hayano H, Nakajima K, Sawase T.
Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like Lesions. Journal of Clinical Medicine. 2023; 12(5):1914.
https://doi.org/10.3390/jcm12051914
Chicago/Turabian Style
Kaneko, Haruka, Shinichiro Kuroshima, Ryohei Kozutsumi, Farah A. Al-Omari, Hiroki Hayano, Kazunori Nakajima, and Takashi Sawase.
2023. "Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like Lesions" Journal of Clinical Medicine 12, no. 5: 1914.
https://doi.org/10.3390/jcm12051914
APA Style
Kaneko, H., Kuroshima, S., Kozutsumi, R., Al-Omari, F. A., Hayano, H., Nakajima, K., & Sawase, T.
(2023). Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like Lesions. Journal of Clinical Medicine, 12(5), 1914.
https://doi.org/10.3390/jcm12051914